Codexis (CDXS) Amortization of Deferred Charges (2020 - 2026)
Codexis' (CDXS) quarterly Amortization of Deferred Charges came in at $935000.0 in Q1 2026, up 232.74% year-on-year from $281000.0 in Q1 2025, and up 207.1% quarter-over-quarter from -$873000.0 in Q4 2025.
Codexis (CDXS) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Codexis' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $935000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 232.74% year-over-year to $935000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 80.72% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 47.46% from the prior year.
- Amortization of Deferred Charges rose to $935000.0 in Q1 2026 per CDXS's latest filing, from -$873000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $3.6 million in Q3 2023 and bottomed at -$3.6 million in Q4 2023.
- The 5-year median for Amortization of Deferred Charges is $291000.0 (2025), against an average of $183823.5.
- Across the five-year window, Amortization of Deferred Charges plunged 523.65% in 2022 and jumped 242.68% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at -$3.6 million in 2022, then fell by 0.8% to -$3.6 million in 2023, then surged by 59.45% to -$1.5 million in 2024, then soared by 40.97% to -$873000.0 in 2025, then soared by 207.1% to $935000.0 in 2026.
- Per Business Quant, the three latest CDXS Amortization of Deferred Charges figures stand at $935000.0 (Q1 2026), -$873000.0 (Q4 2025), and $1.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Codexis | 145.68 Mn | 80.54 Mn | 13.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 935,000.00 |
| Mar 31, 2026 | 935,000.00 |
| Dec 31, 2025 | -873,000.00 |
| Dec 31, 2025 | -873,000.00 |
| Sep 30, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 291,000.00 |
| Jun 30, 2025 | 291,000.00 |
| Mar 31, 2025 | 281,000.00 |
| Mar 31, 2025 | 281,000.00 |
| Dec 31, 2024 | -1.48 Mn |
| Dec 31, 2024 | -1.48 Mn |
| Sep 30, 2024 | 2.02 Mn |
| Sep 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 263,000.00 |
| Mar 31, 2024 | 82,000.00 |
| Mar 31, 2024 | 82,000.00 |
| Dec 31, 2023 | -3.65 Mn |
| Dec 31, 2023 | -3.65 Mn |